Achieve Life Sciences Completes Key Study on Cytisinicline for Renal Impairment

Achieve Life Sciences ((ACHV)) announced an update on their ongoing clinical study.

Achieve Life Sciences recently completed a Phase I study titled A Phase I, Open-Label Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose. The study aimed to understand how cytisinicline, an investigational drug, is processed in the body among individuals with varying degrees of renal impairment compared to those with normal renal function. Additionally, it sought to assess the drug’s removal through dialysis, which is significant for tailoring treatments for patients with kidney issues.

The intervention being tested is cytisinicline, administered as a 3 mg oral tablet. It is designed to help individuals quit smoking by reducing nicotine cravings and withdrawal symptoms.

The study followed a non-randomized, parallel intervention model without masking, focusing on treatment as its primary purpose. Participants were divided into five groups based on their renal function, ranging from normal to end-stage renal disease (ESRD) undergoing dialysis.

The study began on January 10, 2023, and was completed as of the last update on July 8, 2025. These dates are crucial as they mark the progression and completion of the study, providing a timeline for data analysis and potential market entry.

This update could positively influence Achieve Life Sciences’ stock performance by demonstrating progress in their clinical pipeline, potentially enhancing investor confidence. The study’s results could also impact the competitive landscape, especially if cytisinicline proves effective for patients with renal impairments, offering a unique market advantage.

The study is completed, with further details available on the ClinicalTrials portal.